Mercury Biopharmaceutical (ROCO:6932) Long-Term Debt: NT$38.10 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6932 Mercury Biopharmaceutical Corp ROCO:6932
23 GF Score
Price NT$5.42
GF Value NT$36.00
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Mercury Biopharmaceutical Long-Term Debt?

Mercury Biopharmaceutical ROCO:6932 -4.41% 23 Long-Term Debt is NT$38.10 Mil as of Dec. 2025. GuruFocus rates ROCO:6932 with a GF Score™ of 23/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review.

Mercury Biopharmaceutical's Long-Term Debt for the quarter that ended in Dec. 2025 was NT$38.10 Mil.

Mercury Biopharmaceutical's quarterly Long-Term Debt declined from Dec. 2024 (NT$40.39 Mil) to Jun. 2025 (NT$39.16 Mil) and declined from Jun. 2025 (NT$39.16 Mil) to Dec. 2025 (NT$38.10 Mil).

Mercury Biopharmaceutical's annual Long-Term Debt declined from Dec. 2023 (NT$41.60 Mil) to Dec. 2024 (NT$40.39 Mil) and declined from Dec. 2024 (NT$40.39 Mil) to Dec. 2025 (NT$38.10 Mil).

Mercury Biopharmaceutical  (ROCO:6932) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Mercury Biopharmaceutical Long-Term Debt Related Terms

Mercury Biopharmaceutical Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Mercury Biopharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercury Biopharmaceutical Long-Term Debt Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 41.60 41.60 40.39 38.10

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.60 41.43 40.39 39.16 38.10
ROCO:6932
23GF Score
Mercury Biopharmaceutical Corp ROCO:6932
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$38.10 Mil mean?
Mercury Biopharmaceutical (ROCO:6932) has a Long-Term Debt of NT$38.10 Mil as of Dec. 2025.
Is Mercury Biopharmaceutical's Long-Term Debt too high?
Mercury Biopharmaceutical's current Long-Term Debt is NT$38.10 Mil. Overall, Mercury Biopharmaceutical has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Long-Term Debt compare to ZTS?
Mercury Biopharmaceutical's Long-Term Debt of NT$38.10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Mercury Biopharmaceutical's current Long-Term Debt is NT$38.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.42 — trading 84.9% below its estimated fair value. The current Long-Term Debt is NT$38.10 Mil. Mercury Biopharmaceutical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Long-Term Debt is NT$38.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?

Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued. The current stock price of NT$5.42 is trading 84.9% below its estimated GF Value™ of NT$36.00. GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:6932:

  • Long-Term Debt: NT$38.10 Mil
  • GF Value™: NT$36.00 vs. price of NT$5.42 (84.9% below fair value)
  • GF Score™: 23/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mercury Biopharmaceutical Business Description

Address No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
23GF Score

Get the complete analysis for ROCO:6932

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$5.42
Price
NT$36.00
GF Value